This Illinois semi-private country club has changed hands after a bankruptcy
Pekin Country Club, just south of Peoria, Illinois, is under new ownership.
Brothers Jay and Shaun Schlosser said they purchased the club from Pekin Country Club, Inc. Shaun Schlosser did not disclose the price, but the club last fall was listed at $1.95 million with the commercial real estate agency Crexi and the commercial real estate marketplace LoopNet.
The property features an 18-hole championship golf course with four sets of tees for various skill levels, as well as a state-of-the-art practice facility. Public records show Pekin Country Club, Inc. filed for Chapter 11 bankruptcy in March 2023 with the U.S. Bankruptcy Court Central District of Illinois.
Schlosser said he plans to open the golf course to the public on Mondays and to open the country club's restaurant by early May. He also intends to offer discounted club memberships until Memorial Day weekend. New members joining by Memorial Day will pay $400 a month for the first year rather than the regular $450 monthly rate.
'I was raised on a golf course in Decatur,' Schlosser said. "My dad (Gary Schlosser) was a golf pro, and I've always wanted to get into the golf business. We found the listing online, came to have a look around last November, and thought it was worth investing in.'
Pekin Country Club is located at 310 Country Club Drive, Pekin.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
SAN DIEGO and CALGARY, AB, July 23, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, hosted a key opinion leader (KOL) webinar featuring leading physicians in the fields of oncology and immunotherapy discussing pelareorep's robust clinical data and how it fits in the evolving treatment landscape for pancreatic and gastrointestinal (GI) cancers. The KOLs provided individual presentations and then participated in a roundtable Q&A discussion. A replay of the full conversation can be found by clicking here. A selection of key takeaways includes: The meaningful survival benefit demonstrated by pelareorep-based treatment combinations in first-line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC) patients across randomized and single-arm clinical studies necessitates evaluating pelareorep in a registration-enabling study in 1L mPDAC. Immunotherapies have not yet been approved to treat mPDAC patients, illustrating an unmet need, which provides an opportunity for an immunologically active agent like pelareorep to deliver an impactful clinical benefit in this challenging indication. The combination of pelareorep and chemotherapy would be an appealing treatment option for 1L mPDAC patients, even with the presence of RAS inhibitors in the treatment paradigm. Translational data from multiple mPDAC and colorectal cancer clinical trials validate pelareorep's mechanism of action, showing that it replicates in tumors, stimulates chemokine expression, and induces the expansion of tumor-infiltrating lymphocytes (TILs), which correlates with a reduction in tumor size. "I want to thank our esteemed panel of oncologists for their meaningful contributions to our KOL event," said Jared Kelly, Chief Executive Officer of Oncolytics. "Their insights underscore a critical and timely message: pelareorep is a compelling immunotherapy platform that is well situated for combination strategies and a highly differentiated asset for pharma partners looking to expand or establish leadership in GI oncology. We are committed to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers." About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @oncolytics. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our commitment to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers; our plans to advance pelareorep into registration enabling studies in metastatic breast cancer and pancreatic cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. Company Contact Jon PattonDirector of IR & Communicationjpatton@ Investor Relations for Oncolytics Mike MoyerLifeSci Advisors+1-617-308-4306mmoyer@ Media Contact for Oncolytics Owen BlaschakLifeSci Communicationsoblaschak@ Logo - View original content to download multimedia: SOURCE Oncolytics Biotech® Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
an hour ago
- Miami Herald
Rivian plans to open U.K. tech office
Rivian has announced plans to open an office in London "to further the company's AI and autonomous driving ambitions." The new office would complement an existing Rivian tech office in Palo Alto, California, according to a company press release. "Our connected vehicles improve over time through over-the-air updates-and the work the team will do in the U.K. will accelerate our plans and ensure our vehicles remain one of the most technologically advanced and appealing on the road," James Philbin, Rivian vice president of autonomy and AI, said in a statement. The work at the new London office is expected to build on the Rivian Autonomy Platform, the driver-assist sensor and computing suite that debuted with what the automaker calls its "second-generation" models. These are the updated versions of the R1S and R1T that debuted for the 2025 model year looking the same outside, but with numerous hardware changes underneath. Rivian's most sophisticated driver-assist system currently allows for hands-free driving as long as drivers keep their eyes on the road, but the automaker believes it can achieve higher levels of automation by leveraging data collected from the growing fleet of newer vehicles. Rivian hopes to construct what it calls a "Large Driving Model" that can understand "complex driving scenarios," paving the way for increased automation. Back in the U.S., Rivian also recently announced a new East Coast headquarters in Atlanta, not far from the automaker's planned second factory. That $5 billion project was announced in 2021, initially targeting a 2024 opening, but construction was later paused, pushing back the opening to 2027 and then 2028. Late last year, Rivian was awarded a $6.4 billion conditional loan from the federal government that could be crucial to funding the plant's completion. A $5.8 billion joint venture with the Volkswagen Group, which will give the German automotive behemoth access to Rivian's zonal electrical architecture and software, should also help put the company on the firmer financial footing as it undertakes the launch of its lower-priced R2 electric SUV. For now, though, things are still a bit tenuous. At the end of last month, Rivian laid off 140 employees, representing about 1% of its workforce, although they were reportedly encouraged to apply at other open positions within the company. Copyright 2025 The Arena Group, Inc. All Rights Reserved.
Business Wire
an hour ago
- Business Wire
Orases Hosts Ribbon-Cutting to Celebrate 25 Years Building Custom Software Innovations
FREDERICK, Md.--(BUSINESS WIRE)-- Orases, an AI-first custom software development firm and a five-time honoree on the Inc. 5000 list of fastest-growing private companies, has marked its 25th year of business. The company celebrated the milestone with a ribbon-cutting ceremony at its Frederick headquarters. The event commemorated a quarter-century of growth and highlighted the company's long-standing commitment to both technology innovation and community development. "To mark this 25-year milestone surrounded by our dedicated team, valued partners, and leaders from the community was the perfect testament to our journey," said Nick Damoulakis, CEO of Orases. "It has always been our belief that true success isn't just about growth or technological innovation, but about building lasting relationships and sharing that success with the community that helped build you." During the ceremony, Orases was presented with four proclamations from Maryland state and Frederick County officials, recognizing the company's contributions to the regional economy and technology sector. "Orases has been a driving force in Frederick's technology sector, creating jobs and attracting talent to our region," stated Rick Weldon, President and CEO of the Frederick County Chamber of Commerce. "Their success story demonstrates what's possible when innovative companies choose to plant their roots in Frederick and grow with our community." Orases is a co-founder of TechFrederick, an organization supporting the area's technology ecosystem, and maintains a decade-long partnership with the LYNX program to prepare high school students for careers in technology. Through these programs, Orases actively invests in the long-term vitality of its local technology community. About Orases Established in 2000, Orases is a custom software development and AI consulting company that helps organizations solve complex challenges and unlock new growth opportunities. We blend deep industry expertise, decades of hands-on tech experience, and AI-enabled development practices to deliver solutions that are technically sound and strategically built to solve unique business problems. Orases has partnered with leading brands, including the NFL, NPR, and Kimberly-Clark, to define strategic visions, rapidly prototype solutions, and bring features to market faster. Visit us at
